Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized crossover study of oral PHA-022121 (PHVS416) for acute hereditary angioedema attacks
2020-003445-11Phase 2Completed
- Sponsor
- Pharvaris
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucrictibant in hereditary angioedema (HAE) (4 arms), sponsored by Pharvaris. Primary endpoint: Change in 3-symptom composite VAS (VAS-3) score at 4 hours. Started Oct 2020; status: completed.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2020-003445-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003445-11.